Daliresp is a prescription medication that contains the active ingredient roflumilast. It belongs to the therapeutic class of phosphodiesterase-4 (PDE4) inhibitors and is formulated as a 500 mg oral pill. In Hong Kong, Daliresp is regulated by the Department of Health and is available only with a physician’s prescription.
The drug is marketed primarily for the management of chronic obstructive pulmonary disease (COPD) with an emphasis on reducing the risk of exacerbations. While it is sometimes discussed in the broader context of “asthma & breathing” disorders, its approved indication is limited to COPD; it is not authorized for the routine treatment of asthma in Hong Kong.
Roflumilast is a selective phosphodiesterase-4 inhibitor. PDE4 is an enzyme that breaks down cyclic adenosine monophosphate (cAMP) inside inflammatory cells of the airways. By blocking PDE4, roflumilast raises intracellular cAMP levels, which leads to:
The onset of anti-inflammatory activity is gradual, typically becoming noticeable after several weeks of regular use. The drug’s effect persists as long as the medication is taken, with a half-life of approximately 20-30 hours, supporting once-daily dosing in most practice settings.
Approved Indication (Hong Kong):
Roflumilast is not approved for the routine treatment of asthma, allergic rhinitis, or other respiratory conditions in Hong Kong. Use for these unapproved conditions would be considered off-label and should only occur under specialist supervision.
Current peer-reviewed literature does not provide robust evidence supporting routine off-label use of roflumilast for asthma or other non-COPD respiratory disorders. Therefore, this section is omitted.
If any of these conditions apply, the prescribing clinician must evaluate the risk-benefit balance before initiating therapy.
Note: Patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and dietary supplements to their healthcare provider before starting Daliresp.
Patients should maintain regular follow-up appointments with their respiratory specialist or primary care physician to evaluate treatment efficacy and safety.
This article provides educational information about Daliresp and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Daliresp works by reducing airway inflammation through PDE4 inhibition, whereas bronchodilators primarily relax smooth muscle to widen the airways. This different mechanism helps lower the frequency of COPD exacerbations rather than providing immediate relief of breathlessness.
Yes, roflumilast is often prescribed as an add-on therapy to inhaled corticosteroids and long-acting bronchodilators for patients with severe COPD. However, clinicians should monitor for additive side effects such as increased risk of infection.
Dosage adjustment is generally not required for mild renal impairment, but patients with moderate to severe kidney disease should have their renal function assessed and dosing may need modification under medical supervision.
Because roflumilast targets inflammation, clinical benefits in reducing exacerbation rates typically emerge after several weeks to a few months of consistent therapy.
Roflumilast may cause mild elevations in blood glucose; patients with diabetes should have their glycemic control monitored more closely after starting therapy.
No strict dietary restrictions are required, but taking the pill with a light snack can lessen gastrointestinal discomfort.
There is no evidence that roflumilast interferes with vaccine efficacy. Patients can receive routine vaccinations, but they should discuss timing with their healthcare provider.
Persistently severe diarrhea warrants medical evaluation; the prescriber may consider dose reduction, temporary discontinuation, or supportive treatments such as rehydration.
Coverage depends on the individual’s enrollment in specific health benefit plans. Patients should verify reimbursement eligibility with their insurer or the Hospital Authority.
Unused tablets should be returned to a pharmacy or disposed of according to the Hong Kong Department of Health’s recommended medication waste protocols, avoiding flushing or throwing them in household trash.
